EUMelaReg PD-SEQ project accepted at SMR congress 2023
We are pleased to report that the EUMelaReg PD-SEQ project abstract has been accepted for poster presentation at the upcoming Society for Melanoma Research 20th International Congress 2023 in Philadelphia (Abstract title: Efficacy of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment. A EUMelaReg outcome analysis.) Treatment of patients with BRAF-V600-mutated metastatic melanoma with BRAF and MEK inhibitors or immune checkpoint inhibitors with anti-PD1 antibodies or anti-PD1/CTLA4 combinations has significantly improved patient outcomes compared with previous standards of care. A total of 1.861 patients with BRAF V600-mutated, unresectable, metastatic melanoma who received either BRAF/MEKi or a single anti-PD1 ICI as first-line treatment were evaluated based on data from the EUMelaReg registry. In summary, the results suggest that anti-PD1 as a single agent may be a valuable option for certain patients with BRAF V600-mutated metastatic melanoma.